Is Compounded Semaglutide Safe? Compounded vs Brand-Name GLP-1s

Last reviewed: 19 September 2026

Are compounded GLP-1s FDA-approved?

No. The FDA states: “compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.” That applies to every compounded semaglutide and tirzepatide product, whoever prescribes or dispenses it.

The agency’s own recommendation is narrow: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” Brand-name products such as Wegovy, Zepbound and Foundayo have been through that review, and each carries FDA-reviewed prescribing information with a fixed dose-escalation schedule.

Compounding itself is legal. A licensed pharmacist or physician may compound a drug for a patient under conditions set by federal law. What differs is the evidence behind the product you receive. Which GLP-1s are FDA-approved for weight loss lists the five approved products.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A compounder is a state-licensed pharmacy or physician filling prescriptions for individual patients; a 503B outsourcing facility registers with the FDA and is held to manufacturing standards. The FDA’s compounding Q&A puts the gap plainly: “Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements”, while drugs compounded in a state-licensed pharmacy under section 503A “are not”.

Outsourcing facilities “are inspected by FDA according to a risk-based schedule and are subject to increased quality standards”. For pharmacies not registered as outsourcing facilities, the same page says state boards of pharmacy “have primary responsibility for the day-to-day oversight”.

A telehealth brand is usually neither. TMates’ site states that “TMates is not a 503A or 503B compounding facility”. The program arranges the prescriber and passes the prescription to a pharmacy, so the pharmacy’s category is the one that matters. Ask for its name.

Is compounded semaglutide the same as Wegovy or Ozempic?

No. The FDA’s Q&A asks “Are compounded drugs and generic drugs the same?” and answers “No”. A generic drug is approved by the FDA and must establish therapeutic equivalence to the brand-name drug, “while a compounded drug is not approved by FDA”.

Some programs say this in their own terms. OMZO’s terms state that a compounded medication “is not a ‘generic’ version of an FDA-approved drug” and that the company makes no claim that its formulations are equivalent to, or will produce the same clinical outcomes as, any FDA-approved drug.

Why were compounded GLP-1s so widely available, and what changed?

They were widely available because semaglutide and tirzepatide were on the FDA’s drug shortage list, which relaxes the limits on copying an approved drug. Both shortages have ended. The FDA determined the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025.

The agency gave compounders a wind-down period for semaglutide: until April 22, 2025 for 503A pharmacies and until May 22, 2025 for 503B outsourcing facilities. After that, the ordinary rules apply. A 503A pharmacy may not compound “regularly or in inordinate amounts” drugs that are “essentially copies of a commercially available drug product”, and section 503B restricts outsourcing facilities from making drugs that are essentially a copy of an approved one.

The pressure has continued. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, “finding no clinical need for outsourcing facilities to compound these drugs from bulk substances”, with public comments due by June 29, 2026.

The practical consequence is that a compounded product offered today can be changed or withdrawn. Ask a program what happens to your plan and price if that occurs. Cancelling, pausing and renewals explains what prepaid plans refund.

What safety problems has the FDA reported with compounded GLP-1s?

Dosing errors are the best documented. The FDA’s alert on compounded injectable semaglutide reports adverse events, “some requiring hospitalization”, in which “patients administered five to 20 times more than the intended dose”. It attributes these to unfamiliarity with drawing medication from a vial into a syringe, and to confusion between units of measurement.

The FDA’s concerns page, current as of September 1, 2026, adds five more:

• Doses beyond the label. Adverse event reports involve compounded products prescribed at higher doses, more often, or escalated faster than the approved labeling.
• Salt forms. Some compounded semaglutide may be semaglutide sodium or semaglutide acetate, which the FDA calls “different active ingredients than are used in the approved drugs”.
• Multi-dose vials. Contamination risk rises after 28 days from first use.
• Shipping temperature. The agency has received complaints of products arriving warm or with inadequate ice packs.
• Fraudulent products. Some labels name compounding pharmacies that do not exist, or licensed pharmacies that did not make the product.

Brand-name GLP-1s have side effects too, and the labels document them in detail. GLP-1 side effects: what the labels report covers those; the difference here is that a compounded product has no label and no pre-market review.

What has the FDA done about telehealth marketing of compounded GLP-1s?

It has sent warning letters in two waves. On March 3, 2026 the FDA announced 30 warning letters to telehealth companies “for making false or misleading claims regarding compounded GLP-1 products”, the second group since a crackdown began in September 2025. It named the main violations as “claims implying sameness with FDA-approved products” and products branded with the telehealth firm’s name, “implying they are the compounder”.

Three programs DoIQualify reviews have received such letters: Direct Meds on September 9, 2025, MEDVi on February 20, 2026 and Eden on June 8, 2026. We have not established the current status of any of them. The Direct Meds, MEDVi and Eden reviews set out what each letter said.

A warning letter concerns marketing claims. It is not a finding that a product harmed anyone, and it is not a recall.

What are the FDA’s red flags for a telehealth seller?

The FDA lists seven. Be wary if a company:

• claims the compounded drug is the same as an FDA-approved drug;
• offers medicine at deep discounts or prices that seem too good to be true;
• sends medicine that looks different from what was pictured, or arrives in broken packaging or without instructions for use;
• does not require screening and a prescription by a licensed doctor;
• has no licensed doctor available to answer questions after you receive the medication;
• makes spelling errors on the label or gives an incorrect pharmacy address;
• puts a pharmacy name on the label that you think might be fraudulent.

What should you ask a program that prescribes compounded medication?

Ask five questions, and treat a missing answer as an answer.

• Which pharmacy will dispense it, in which state is it licensed, and is it a 503A pharmacy or a 503B outsourcing facility?
• Is the active ingredient semaglutide or tirzepatide base, or a salt form?
• How is each dose measured, in which units, and who do I call with a dosing question?
• How is it shipped, and what should I do if it arrives warm?
• What happens to my prescription and price if this compounded product stops being available?

Programs differ on the first question. In their terms or FAQ, JoinSkinny, Lttl, Sunlight and CareBareRX name their partner pharmacies; TMates, OMZO and TrimRx did not when we read them on Sep 19, 2026. The compare table marks which programs offer compounded, brand-name or both.

Neither category is automatically the right one for you. The DoIQualify quiz shows whether you may meet common criteria and lets you state a preference for FDA-approved brand-name medication; a result is not an approval. What each route costs is in What GLP-1s cost in 2026.

Compounded GLP-1 FAQ

This article is informational and not medical advice. A licensed clinician makes every prescribing decision. We may earn a referral fee if you enroll through our links; it does not change scores or positions. Medical disclaimer · How we rankGLP-1 price list